ACM
RVNC

Aubrey Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Aubrey Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,170
Closed -$172K – 52
2021
Q3 		$172K Buy
+6,170
New +$176K 0.05% 43

Other funds holding RVNC

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Aubrey Capital Management's RVNC Position: Q4 2021 in Review

Aubrey Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2021, closing a stake of 6,170 shares — an estimated $172K sold.

Aubrey Capital Management first reported a position in RVNC in Q3 2021 and held it in 1 quarter. The position peaked at $172K in Q3 2021. 151 funds tracked by Wall St. Rank hold RVNC as of Q4 2021.

  • Aubrey Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
  • Aubrey Capital Management sold 6,170 Revance Therapeutics, Inc. shares in Q4 2021, an estimated $172K.
  • Aubrey Capital Management first reported a position in Revance Therapeutics, Inc. in Q3 2021 and held it in 1 quarter.
  • Aubrey Capital Management's Revance Therapeutics, Inc. position peaked at $172K in Q3 2021.
  • 151 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2021.

Based on Aubrey Capital Management's 13F filing for Q4 2021, filed 9 Feb 2022.